Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02027662 | Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules | PHASE2 | COMPLETED | 61 | — | — | Jan 1, 2014 | Jun 1, 2015 | Jun 10, 2015 | 11 | Germany |
| Arm | Type | Description |
|---|---|---|
| Osvaren Granules | EXPERIMENTAL | Osvaren Granules |
| Osvaren film-coated tablets | ACTIVE_COMPARATOR | Osvaren film-coated tablets |
| Name | Type | Description |
|---|---|---|
| Osvaren Granules | DRUG | - |
| Osvaren film-coated tablets | DRUG | - |
Inclusion Criteria: * Signed written informed consent form is obtained prior to starting the screening visit * Male and female patients 18-80 years of age with dialysis dependent renal failure (CKD 5D) * Patients have been on 3x/week in-centre renal replacement therapy for at least 2 months on eith...